Immunohistochemical expression of hypoxia inducible factor-1alpha and its downstream molecules in sarcomatoid renal cell carcinoma.

[1]  W. Kaelin,et al.  Clusterin is a secreted marker for a hypoxia-inducible factor-independent function of the von Hippel-Lindau tumor suppressor protein. , 2006, The American journal of pathology.

[2]  J. Lam,et al.  Role of molecular markers in the diagnosis and therapy of renal cell carcinoma. , 2005, Urology.

[3]  R. Motzer,et al.  Therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: biology, clinical results and future development , 2005, BJU international.

[4]  J. Lam,et al.  Renal cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy. , 2005, The Journal of urology.

[5]  S. Signoretti,et al.  Carbonic Anhydrase IX Expression Predicts Outcome of Interleukin 2 Therapy for Renal Cancer , 2005, Clinical Cancer Research.

[6]  S. Horvath,et al.  Prognostic value of carbonic anhydrase IX and KI67 as predictors of survival for renal clear cell carcinoma. , 2004, The Journal of urology.

[7]  J. Cheville,et al.  Sarcomatoid Renal Cell Carcinoma: An Examination of Underlying Histologic Subtype and an Analysis of Associations With Patient Outcome , 2004, The American journal of surgical pathology.

[8]  Steve Horvath,et al.  Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[9]  S. Culine,et al.  Doxorubicin and ifosfamide in patients with metastatic sarcomatoid renal cell carcinoma: a phase II study of the Genitourinary Group of the French Federation of Cancer Centers. , 2002, The Journal of urology.

[10]  W. Kaelin,et al.  Molecular basis of the VHL hereditary cancer syndrome , 2002, Nature Reviews Cancer.

[11]  A. Belldegrun,et al.  Sarcomatoid renal cell carcinoma , 2001 .

[12]  H. Gröne,et al.  Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-1alpha in clear cell renal carcinomas. , 2001, Cancer research.

[13]  H. Moch,et al.  Sarcomatoid Differentiation in Renal Cell Carcinoma: A Study of 101 Cases , 2001, The American journal of surgical pathology.

[14]  P. Bhargava,et al.  Sustained response of sarcomatoid renal-cell carcinoma to MAID chemotherapy: case report and review of the literature. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  R. Figlin,et al.  Sarcomatoid renal cell carcinoma: biologic behavior, prognosis, and response to combined surgical resection and immunotherapy. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  J. Cheville,et al.  Rare expression of KIT and absence of KIT mutations in high grade renal cell carcinoma. , 2006, The Journal of urology.

[17]  R. Figlin,et al.  Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  R. Amato.  Therapy for Patients with Uncommon Histologic Varieties of Renal Cell Carcinoma , 2000 .

[19]  A. Novick,et al.  Renal cell carcinoma : molecular biology, immunology, and clinical management , 2000 .

[20]  S. Culine,et al.  Treatment of sarcomatoid renal cell carcinoma: is there a role for chemotherapy? , 1995, European urology.